Hemogenyx Pharmaceuticals PLC Announces Collaboration with Cellin Technologies

Hemogenyx Pharmaceuticals plc (LSE: HEMO) said it has signed a definitive collaboration agreement with Cellin Technologies OÜ for manufacturing and clinical implementation of its HG-CT-1 CAR-T therapy in Estonia. The deal converts a previously non-binding letter of intent into binding commitments and is aimed at generating the company’s first potential near-term revenues while building real-world clinical data alongside its ongoing Phase I trial. Under Estonia’s Hospital Exemption framework, Cellin will become Hemogenyx’s exclusive manufacturing and operational partner for five years at its GMP facility in Tallinn, following about four months of technology transfer and an approximately 90-day regulatory review.